As r‐ITIH1 intervention had an effect in the HCC PDX model and galunisertib has already been used in clinical HCC treatment, we hypothesized that r‐ITIH1 might synergize with galunisertib to suppress HCC development in vivo. The gene discussed is ITIH1; the disease is hepatocellular carcinoma.